Induced pluripotent stem cell models of myeloid malignancies and clonal evolution.
Induced pluripotent stem cell models of myeloid malignancies and clonal evolution.
复制标题
DOI：
10.1016/j.scr.2021.102195
复制
发表时间：
2021-04
影响因子：
1.2
通讯作者：
Doulatov, Sergei
中科院分区：
文献类型：
--
作者：
Reilly, Andreea;Doulatov, Sergei
将遗传性疾病患者的细胞重编程为多能性是理解疾病生物学的一个有希望的途径。在过去的十年中，已经报道了许多遗传性单基因血液病的诱导多能干细胞（iPSC）模型。然而，iPSC用于血液恶性肿瘤建模的应用仅在最近才被探索。血液恶性肿瘤包括一系列以获得体细胞突变和染色体畸变为标志的遗传异质性疾病。这种遗传异质性对iPSC建模提出了独特的挑战，但也有机会捕获遗传上不同的状态并生成从正常到恶性造血逐步进展的模型。在这里，我们简要回顾了这一领域的现状，突出了目前的模型获得性恶性和恶性血液疾病和克隆进化，以及挑战，包括障碍，重新编程和分化的iPSC真正的造血干细胞。
Reprogramming of cells from patients with genetic disorders to pluripotency is a promising avenue to understanding disease biology. A number of induced pluripotent stem cell (iPSC) models of inherited monogenic blood disorders have been reported over the past decade. However, the application of iPSCs for modeling of hematological malignancies has only recently been explored. Blood malignancies comprise a spectrum of genetically heterogeneous disorders marked by the acquisition of somatic mutations and chromosomal aberrations. This genetic heterogeneity presents unique challenges for iPSC modeling, but also opportunities to capture genetically distinct states and generate models of stepwise progression from normal to malignant hematopoiesis. Here we briefly review the current state of this field, highlighting current models of acquired pre-malignant and malignant blood disorders and clonal evolution, and challenges including barriers to reprogramming and differentiation of iPSCs into bona fide hematopoietic stem cells.
登录
查看更多内容
影响因子：
11.8
作者：
Böiers C;Richardson SE;Laycock E;Zriwil A;Turati VA;Brown J;Wray JP;Wang D;James C;Herrero J;Sitnicka E;Karlsson S;Smith AJH;Jacobsen SEW;Enver T
通讯作者：
Enver T
影响因子：
23.9
作者：
Doulatov, Sergei;Vo, Linda T.;Chou, Stephanie S.;Kim, Peter G.;Arora, Natasha;Li, Hu;Hadland, Brandon K.;Bernstein, Irwin D.;Collins, James J.;Zon, Leonard I.;Daley, George Q.
通讯作者：
Daley, George Q.
影响因子：
17.1
作者：
Doulatov S;Vo LT;Macari ER;Wahlster L;Kinney MA;Taylor AM;Barragan J;Gupta M;McGrath K;Lee HY;Humphries JM;DeVine A;Narla A;Alter BP;Beggs AH;Agarwal S;Ebert BL;Gazda HT;Lodish HF;Sieff CA;Schlaeger TM;Zon LI;Daley GQ
通讯作者：
Daley GQ
影响因子：
3.6
作者：
Cai SF;Levine RL
通讯作者：
Levine RL
影响因子：
21.3
作者：
Ditadi A;Sturgeon CM;Tober J;Awong G;Kennedy M;Yzaguirre AD;Azzola L;Ng ES;Stanley EG;French DL;Cheng X;Gadue P;Speck NA;Elefanty AG;Keller G
通讯作者：
Keller G